Colorectal Neoplasms
Conditions
Keywords
Colorectal Cancer, Antibody Drug Conjugate, Disitamab Vedotin, Tislelizumab
Brief summary
Among patients with colonrectal cancer, 5% were HER-2 positive, but the immunohistochemical results were mostly HER-2 2 +, which did not meet the indications of HER-2 targeting drugs. Disitamab Vedotin , which was listed in China last year, achieved similar results in HER-2 2+ and 3+, according to a clinical trial for breast cancer, suggesting that patients with colonrectal cancer may benefit from it. Tislelizumab is a PD-1 monoclonal antibody, which has been approved for a variety of tumors. It was reported that anti-HER-2 treatment can improve the tumor immune microenvironment and improve the efficacy of immunotherapy. At the same time, our previous studies showed that anti-PD-1 combined with Disitamab Vedotin can significantly inhibit the growth of colon tumor in mice. Therefore, Disitamab Vedotin and Tislelizumab were used in this study. This prospective clinical trial may bring new hope for the treatment of HER-2 positive CRC patients.
Interventions
DRUGDisitamab vedotin
2.0mg/kg，q2w
DRUGTislelizumab
400mg，q6w
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed the consents voluntarily; 2. All genders, age 18 or above; 3. Histological or cytological documentation of local advanced or metastatic unresectable colorectal carcinoma; 4. Patients with HER-2 overexpression (HER-2 IHC 2+ or IHC 3+) detected by immunohistochemistry; Resampling is recommended for samples over 3 years. 5. Subjects must have failed at treatments including fluoropyrimidine, oxaliplatin and irinotecan; For adjuvant or neoadjuvant chemotherapy, if disease progression occurs during treatment or within 6 months after treatment, it will be recorded as a first-line treatment; 6. Patients who have used anti-PD-1 or anti-PD-L1 inhibitors can be selected after stopping the treatment for more than 6 months; Patients who have used other anti HER-2 drugs with different mechanisms can be selected. 7. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.is necessary 8. Life expectancy of at least 3 months. 9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. 10. Have sufficient heart, lung, liver and kidney functions, and the laboratory examination within 14 days before screening meets the following indicators: i. Hemoglobin Hb ≥ 90 g/L ii. Neutrophil count ANC ≥ 1.5\*10\^9 /L iii. Platelet count PLT ≥ 80\*10\^9 /L iv. Albumin ALB ≥ 35 g/L v. Alanine aminotransferase ALT and aspartate aminotransferase AST ≤ 2.5 times the upper limit of the normal range, and liver metastasis patients ≤ 5 times the upper limit of the normal range. vi. Total bilirubin ≤ 1.5 times, or 2 times the upper limit of normal. vii. Creatinine Scr ≤ upper limit of normal range. viii. Prothrombin: PT-INR ≤ 2.3 or PT \< 6 seconds compared with normal control 11. Subjects must complete the treatment and follow-up on schedule. according to the research plan. 12. No brain metastasis, no spinal cord compression. 13. Subjects agree to use blood samples for study analysis. 14. Women of childbearing age must be negative in pregnancy test and willing to take effective contraceptive measures during the study period.
Exclusion criteria
1. Subjects are severe malnutrition or need tube feeding. 2. Major surgery has been performed within 30 days before treatment. 3. Previous treatment with anti-PD-1 / PD-L1 inhibitor, anti-CTLA-4 inhibitor, ADC drugs targeting HER-2 such as RC48 and T-DM1 within 6 months. 4. Other malignant tumors within 2 years and without cure (Except for patients with other early-stage tumors, after radical treatment, whom the researchers assess the recurrence risk of in the short term is small); 5. Subjects have active autoimmune system diseases that need systemic hormone therapy or anti autoimmune drug therapy. 6. Subjects with immunodeficiency or receiving systemic steroid therapy (prednisone \> 10 mg / day or other equivalent drugs) or other forms of immunosuppressive therapy 7 days before the first dose of combination therapy in this study; 7. Subjects with active infection and still need systemic treatment 7 days before the first dose of therapy in this study. 8. Subjects with uncontrollable systemic diabetes. 9. Subjects with interstitial lung disease, non infectious pneumonia or pulmonary fibrosis; 10. Subjects who have received allogeneic organ or stem cell transplantation in the past. 11. Subjects allergic to the drugs or related components involved in this study. 12. Participating in other interventional clinical studies. 13. The previous anti-tumor related adverses do not return to grade 1 in CTCAE before the first combination therapy. 14. Subjects who have uncontrolled hypertension by drugs, that is, systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg. 15. Thrombotic or hemorrhagic tendency or history within 60 days before the first medication, regardless of the severity. 16. Any serious or unstable medical condition#mental illness or known active alcohol or drug abuse or dependence.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate(ORR) | up to 2 years | The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival(PFS) | From date of subjects until the date of first documented progression or death from any cause, whichever came first, assessed up to 24 months | PFS was defined as the time from assignment to disease progression radiological/clinical or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. |
| Overall Survival (OS) | From assignment of the first subject until 32 death events observed, up to 2 years. | OS is defined as the time from date of assignment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. |
| Disease control rate (DCR) | up to 2 years | DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD). |
| Safety and Feasibility | up to 2 years | Safety is defined as the incidence of Grade 3-4 Treatment-Related Adverse Events (TRAEs) from the day of neoadjuvant therapy to 30 days after surgery or within 90 days after last neoadjuvant treatment. Feasibility of surgery is defined as the incidence of TRAEs causing surgery delay of ≥30 days and/or inoperable patients.Feasibility of surgery is defined as the incidence of TRAEs causing surgery delay of ≥30 days and/or inoperable patients. |
| Duration of Response (DOR) | up to 2 years | DOR is defined as the time from randomization to disease progression or death in patients who achieve complete or partial response. |
Countries
China
Contacts
Primary ContactYanhong Gu, Dr
Backup ContactShiyun Cui, Dr
Outcome results
None listed